Brief: Timber Pharmaceuticals Announces FDA Grant Of Carc Waiver For Tmb-001
05/06/2023 16:03
June 5 (Reuters) - Timber Pharmaceuticals Inc TMBR.A :
* TIMBER PHARMACEUTICALS ANNOUNCES FDA GRANT OF CARC WAIVER
FOR
TMB-001
* TIMBER PHARMACEUTICALS INC - PHASE 3 ASCEND STUDY OF
TMB-001
(TOPICAL ISOTRETINOIN) FOR TREATMENT OF CONGENITAL ICHTHYOSIS IS
70% ENROLLED
Source text for Eikon: ID:nGNXb4L0np
Further company coverage: TMBR.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Trex Wind-Down
See all newsBrief: NYSE American To Suspend Trading Immediately In Timber Pharma
Brief: Timber Pharmaceuticals Receives Court Approval Of All “First Day” Motions To Support Business
Brief: NYSE American to Commence Delisting Proceedings Against Timber Pharmaceuticals
Brief: Timber Pharmaceuticals Says Prior To Filing Of Chapter 11 Case, Debtors Entered Into A "Stalking Horse" Asset Purchase Agreement
Brief: Timber Pharmaceuticals Inc Files For Voluntary Chapter 11 Bankruptcy - Court Filing